

InterMune Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

URL:	https://marketpublishers.com/r/I15405DC0E5BEN.html
Date:	October 15, 2018
Pages:	50
Price:	US\$ 499.00
ID:	I15405DC0E5BEN

InterMune Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between InterMune Inc. and its competitors. This provides our Clients with a clear understanding of InterMune Inc. position in the **Pharmaceuticals and Biotechnology Industry**.

- The report contains detailed information about InterMune Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for InterMune Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.
- The InterMune Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.
- In the part that describes InterMune Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of InterMune Inc. business.

About InterMune Inc.

InterMune, Inc., a biotech company, focuses on developing and commercializing therapies in pulmonology and hepatology primarily in the United States and Europe.

Approved Product

The company's sole approved product is Actimmune, approved for the treatment of patients with severe,

malignant osteopetrosis and chronic granulomatous disease (CGD). It has the rights to develop and commercialize Actimmune for a range of diseases in the United States, Canada, and Japan. The company has an agreement with Boehringer Ingelheim International GmbH (Imukin) in connection with the development and commercialization of interferon gamma-1b in Europe and the rest of the world under the trade name Imukin.

The company has an advanced-stage development pipeline in the pulmonology area and a research and development-stage pipeline in the hepatology area.

Pulmonology: In pulmonology, the company is developing a single therapy for the treatment of IPF. It is developing one clinically advanced compound for the treatment of IPF, pirfenidone. Pirfenidone is an orally available small molecule. Pirfenidone has orphan drug status in the United States and the European Union. Shionogi and Co. Ltd. holds the rights to pirfenidone in Japan, Korea and Taiwan.

Hepatology: In hepatology, the company is developing product candidates to provide expanded treatment options for patients suffering from HCV infection. Its primary compound in hepatology is ITMN-191, an orally available HCV protease inhibitor. The company is conducting a Phase 2b clinical trial of this compound. Its HCV protease inhibitor program is being conducted under its license and collaboration agreement with Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.

In 2008, the company, together with Roche and Pharmasset, Inc. (Pharmasset) announced the initiation of INFORM-1, a dual combination clinical trial investigating the combination of two oral antiviral molecules in the absence of interferon. The initial study would evaluate the safety and combined antiviral activity of ITMN-191 and R7128, a polymerase inhibitor, in 14 days of combination therapy in treatment-naïve patients infected with HCV genotype 1. In 2009, together with Roche, the company began a Phase IIb study testing RG7227 in combination with PEGASYS (peginterferon alfa-2a) and COPEGUS (ribavirin), the current standard of care (SOC) in HCV.

Product Distribution

In the United States, Actimmune is sold primarily to distributors and specialty pharmacies who distribute directly to patients. During the year ended December 31, 2009, the primary specialty pharmacies and distributors for Actimmune were CuraScript, Inc., Nova Factor, Inc., and Caremark, Inc.

Agreements

Catalent Pharma Solutions LLC (pirfenidone): In 2009, the company entered into a commercial manufacturing agreement with Catalent Pharma Solutions, LLC (Catalent) to process and encapsulates the API for pirfenidone and to supply it with bulk pharmaceutical pirfenidone product for commercial use.

Competition

The company's competitors include Actelion Pharmaceuticals, Ltd.; Gilead Sciences, Inc.; Schering-Plough Corporation; Gilead, Merck & Co.; Pfizer, Inc.; GlaxoSmithKline; Vertex Pharmaceuticals, Inc.; Medivir; and Tibotec, Inc.

History

InterMune, Inc. was founded in 1998.

The above Company Fundamental Report is a half-ready report and contents are subject to change. It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Table of Content

RESEARCH METHODOLOGY

DISCLAIMER

1. INTERMUNE INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

2. INTERMUNE INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

3. INTERMUNE INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

4. INTERMUNE INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
 - 4.1.1. Income Statement
 - 4.1.2. Balance Sheet
 - 4.1.3. Cash Flow
- 4.2. Financial Ratios
 - 4.2.1. Profitability
 - 4.2.2. Margin Analysis
 - 4.2.3. Asset Turnover
 - 4.2.4. Credit Ratios
 - 4.2.5. Long-Term Solvency
 - 4.2.6. Growth Over Prior Year
 - 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

5. INTERMUNE INC. COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. InterMune Inc. Direct Competitors
- 5.2. Comparison of InterMune Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of InterMune Inc. and Direct Competitors Stock Charts
- 5.4. InterMune Inc. Industry Analysis
 - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
 - 5.4.2. InterMune Inc. Industry Position Analysis

6. INTERMUNE INC. NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

7. INTERMUNE INC. EXPERTS REVIEW¹

- 7.1. Experts Opinion
- 7.2. Experts Estimates

8. INTERMUNE INC. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

10. INTERMUNE INC. IFE, EFE, IE MATRICES²

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

11. INTERMUNE INC. PORTER FIVE FORCES ANALYSIS²

12. INTERMUNE INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF TABLES

InterMune Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
InterMune Inc. Key Executives
Key Executives Biographies¹
Key Executives Compensations¹
InterMune Inc. Major Shareholders
InterMune Inc. History
InterMune Inc. Products
Revenues by Segment
Revenues by Region
InterMune Inc. Offices and Representations
InterMune Inc. SWOT Analysis
Yearly Income Statement Including Trends

Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
InterMune Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
InterMune Inc. Capital Market Snapshot
InterMune Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
InterMune Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
InterMune Inc. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

LIST OF FIGURES

InterMune Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
InterMune Inc. 1-year Stock Charts
InterMune Inc. 5-year Stock Charts
InterMune Inc. vs. Main Indexes 1-year Stock Chart
InterMune Inc. vs. Direct Competitors 1-year Stock Charts
InterMune Inc. Article Density Chart

¹ – Data availability depends on company's security policy.

² – These sections are available only when you purchase a report with appropriate additional types of analyses.

The complete financial data is available for publicly traded companies.

I would like to order:

Product name: InterMune Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Product link: <https://marketpublishers.com/r/I15405DC0E5BEN.html>
Product ID: I15405DC0E5BEN
Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/I15405DC0E5BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**